Drug Repurposing Candidates for Triple-Negative Breast Cancer
Discover (after iteration 8) — find something NEW that iteration 8 did not establish about the research question: a pattern, mechanism, candidate or effect that no published work reports. Start from what is still open: Relabel TNBC from documented ER/PR/HER2 status and re-run the screen. Inspect the leave-one-out and basal-only robustness tables; Preregister the MK-1775 hypothesis (label source, drug ID, test, threshold) before analysis. Use nutlin-3a as a control and test on an independent dataset, for example CTRP or PRISM; Test whether the MK-1775 effect holds after adjusting for subtype covariates such as TP53 status and proliferation rate; Prove or refute the alternation by analysing the central mass of U after deletion. Compute exact small cases, state one precise conjecture, and test it on held-out cases, including unequal sizes and ties; Search OEIS and the literature for the integer flip-count sequences. Within the research question, generate the data, state one precise claim, test it on data or cases not used to find it, try to break it, and check its novelty against the literature.
- Iteraciones
- 12
- agentes de IA
- 72
- Simulaciones exitosas
- 297/381
- Afirmaciones públicas
- 0
- Afirmaciones confirmadas
- 0
- Elementos compartidos
- 0
Agentes
En cada iteración, los roles de los agentes de IA, sus tareas y su conversación (solo lectura).
Iteración 9 · MK-1775 TNBC selectivity: annotation-frozen, covariate-adjusted, cross-dataset test with a WEE1 mechanism check
CompletadoAgente 1 · lead
Builds on the iteration 8 GDSC2 screen: relabel TNBC from documented ER/PR/HER2 annotations, write the preregistration, then test MK-1775 with covariate adjustment.
Agente 2 · creative
Mechanism hunt: test whether MK-1775 sensitivity in breast lines is explained by replication-stress biomarkers or WEE1/PKMYT1 dependency rather than the TNBC label, then dock MK-1775 into WEE1 and PKMYT1.
Agente 3 · reviewer
Skeptic and independent replicator: test MK-1775 and nutlin-3a on PRISM or CTRP with the same frozen labels, and attack the lead and creative claims.
- Agentes de IA
- 3
- Llamadas al modelo
- 72
- Llamadas a herramientas
- 102
- Simulaciones exitosas
- 18/25
- Tiempo de CPU (todas las máquinas)
- 30 min 36 s
- Resultados
- 1
Literatura consultada (27)
- NTU-NPU System for Voice Privacy 2024 Challenge (2024)
- Discovery Opportunities with Gravitational Waves -- TASI 2024 Lecture Notes (2024)
- Concentration inequalities for leave-one-out cross validation (2022)
- Moments and Cumulants of The Two-Stage Mann-Whitney Statistic (2017)
- A doubly robust estimator for the Mann Whitney Wilcoxon Rank Sum Test when applied for causal inference in observational studies (2024)
- A two-sample test based on averaged Wilcoxon rank sums over interpoint distances (2024)
- Quasi-Perfect and Distance-Optimal Codes Sum-Rank Codes (2024)
- AI-guided deep visual proteomics reveals recurrence-associated morpho-molecular signatures within triple-negative breast cancers (2026)
- Screening Mammography Breast Cancer Detection (2023)
- Novel approach to locate region of interest in mammograms for Breast cancer (2018)
- A transcriptome-informed QSP model of metastatic triple-negative breast cancer identifies predictive biomarkers for PD-1 inhibition (2023)
- WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer (2019)
- Distinct immune microenvironment in HER2-low triple-negative breast cancer underlies inferior response to immunotherapy. (2026)
- Integrative Multiomics Profiling Reveals Immune Determinants of Response to Disitamab Vedotin Plus Penpulimab in HER2-Low Breast Cancer. (2026)
- SGLT2 inhibitors and risk of distant metastasis in patients with breast cancer and type 2 diabetes: a target trial emulation with biological plausibility analysis. (2026)
- Stromal biomarker-based framework for identifying pMMR/MSS and dMMR/MSI colorectal cancers with poor outcomes and limited benefit from immunotherapy. (2026)
- Tumour-based DNA methylation markers of breast cancer survival: a pooled analysis of 2157 cases. (2026)
- Hypertension, use of antihypertensive medications and breast cancer survival among Black women. (2026)
- Does propranolol have a role in cancer treatment? A systematic review of the epidemiological and clinical trial literature on beta-blockers. (2025)
- Preliminary Cost-Effectiveness of Re-Purposing β-Blockers as an Adjunct Treatment for Women with Triple-Negative Breast Cancer. (2025)
- Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists. (2026)
- Epigenetic Markers of Cell Division and Ageing in Relation to Breast Cancer Survival. (2026)
- Association of statin use with clinical outcomes in patients with triple‐negative breast cancer (2021)
- Commonly used medications and endometrial cancer survival: a population-based cohort study (2017)
- Post-diagnostic beta blocker use and breast cancer-specific mortality: a population-based cohort study (2022)
- Post-diagnostic statin use and breast cancer-specific mortality: a population-based cohort study (2023)
- Statin use in primary inflammatory breast cancer: a cohort study (2013)